Immuneering Corp
Immuneering Corp (IMRX): 9 pipeline candidates · 2 upcoming catalysts · ~13 mo cash runway · 3 clinical trials. Updated within the last hour.
BioSniper Score
6-factor signal · derived from public data
13.3 months
D/E 0.04
Lead: Phase 3
9 candidates
2 upcoming, next in ~959d
5 buys · 0 sells (180d)
A transparent, data-derived signal for Immuneering Corpacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$267.8M
Cash
$47.3M
Quarterly Burn
$18.4M
Runway
13.3 mo
Revenue
—
Cash Runway vs Catalysts
A catalyst falls after projected cash runway — potential financing / dilution risk before it hits.
Pipeline (9 candidates)
| Drug | Phase |
|---|---|
| atebimetinib | Phase 3 |
| envometinib | Phase 1/Phase 2 |
| gnp | Phase 3 |
| imm-1-104 | Phase 2 |
| imm-1-104 + dabrafenib | Phase 1/Phase 2 |
| imm-1-104 + modified folfirinox | Phase 1/Phase 2 |
| imm-1-104 monotherapy | Phase 1/Phase 2 |
| imm-6-415 | Phase 1/Phase 2 |
| mgnp | Phase 3 |
Upcoming Catalysts (2)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
92
Total value held
$128.0M
| Holder | Shares | Value |
|---|---|---|
| fmr llc | 9,697,938 | $51.1M |
| vanguard capital management llc | 2,288,341 | $12.1M |
| marshall wace, llp | 1,996,585 | $10.5M |
| blackrock, inc. | 1,507,258 | $7.9M |
| millennium management llc | 1,102,712 | $5.8M |
| geode capital management, llc | 637,944 | $3.4M |
| citadel advisors llc | 529,078 | $2.8M |
| connor, clark & lunn investment management ltd. | 400,363 | $2.1M |
| summit financial, llc | 376,749 | $2.0M |
| ubs group ag | 376,284 | $2.0M |
Showing top 10 of 92 institutional holders of Immuneering Corp. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Immuneering Corp's pipeline?
Immuneering Corp (IMRX) has 9 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Immuneering Corp's lead drug candidate?
Immuneering Corp's most advanced tracked candidate is atebimetinib (Phase 3) for Pancreatic Cancer.
What is Immuneering Corp's next catalyst?
Immuneering Corp's next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: A Phase 3 Randomized, Open-Label Study of Atebimetinib in Combination With the Modified Gemcitabine " — expected February 1, 2029.
What is Immuneering Corp's cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Immuneering Corp has approximately 13.3 months of cash runway.
What is Immuneering Corp's market capitalization?
Immuneering Corp's market capitalization is approximately $267.8M.
Get the full picture on Immuneering Corp
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.